Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
Crossref DOI link: https://doi.org/10.1186/s12933-015-0314-0
Published Online: 2015-12-23
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Roden, Michael
,
Merker, Ludwig
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Stella, Peter
Woerle, Hans J.
Broedl, Uli C.
Funding for this research was provided by:
Boehringer Ingelheim
Lilly Deutschland